Last $6.47 USD
Change Today +0.125 / 1.97%
Volume 28.8K
ATNM On Other Exchanges
Symbol
Exchange
NYSE Amex
As of 1:06 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

actinium pharmaceuticals inc (ATNM) Snapshot

Open
$6.46
Previous Close
$6.34
Day High
$6.65
Day Low
$6.31
52 Week High
04/3/14 - $15.00
52 Week Low
08/30/13 - $3.60
Market Cap
182.0M
Average Volume 10 Days
42.5K
EPS TTM
$-0.87
Shares Outstanding
28.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTINIUM PHARMACEUTICALS INC (ATNM)

Related News

No related news articles were found.

actinium pharmaceuticals inc (ATNM) Related Businessweek News

No Related Businessweek News Found

actinium pharmaceuticals inc (ATNM) Details

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer. The company’s products include Actimab-A, an antibody-drug construct that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia; and Iomab-B, an antibody-drug construct, which is used in myeloconditioning for hematopoietic stem cells transplantation in various indications. The company was founded in 2000 and is based in New York, New York.

6 Employees
Last Reported Date: 03/19/14
Founded in 2000

actinium pharmaceuticals inc (ATNM) Top Compensated Officers

Chief Executive Officer, President, Interim C...
Total Annual Compensation: $112.1K
Chief Operating Officer and Chief Medical Off...
Total Annual Compensation: $295.5K
Compensation as of Fiscal Year 2013.

actinium pharmaceuticals inc (ATNM) Key Developments

Actinium Pharmaceuticals, Inc. Announces Launch of Additional Antibody Actinium-225 Labeling Program

Actinium Pharmaceuticals, Inc. initiated development of an additional antibody construct labeled with actinium-225. The antibody has potential to be used in treatment of a number of blood cancers. Preclinical work for this additional antibody will be done at Memorial Sloan Kettering Cancer Center. A significant amount of both clinical and preclinical data for the antibody labeled with other payloads is available from numerous clinical trials in a number of indications. Arming a versatile antibody with actinium-225 will allow further customization of treatment in various blood cancer indications and its use in expanded clinical settings due to very low levels of radiation exposure to medical personnel, other caregivers and environment. Pending successful results of the preclinical work, development will continue in clinical trials. Alpha emitters deposit higher energy over a much shorter distance compared with beta emitters, providing single-cell kill while sparing normal surrounding tissue. Increased cell-specific potency may provide less off-target toxicity, resulting in an approach that decreases relapse rates and is better tolerated by patients. Alpha emitters may prove particularly useful for minimal-residual disease or extramedullary disease (located outside of the bone marrow), as well as in the non- hematopoietic stem cell transplantation (HSCT) setting, if conjugated/connected to select target antigens. Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first demonstrated at Memorial Sloan Kettering Cancer Center.

Actinium Pharmaceuticals, Inc. Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-13-2014 09:30 AM

Actinium Pharmaceuticals, Inc. Presents at Canaccord Genuity 34th Annual Growth Conference, Aug-13-2014 09:30 AM. Venue: InterContinental Hotel, 510 Atlantic Avenue, Boston, MA 02210, United States. Speakers: Kaushik J. Dave, Chief Executive Officer, President, Interim Chief Financial Officer, Principal Accounting Officer and Director.

Actinium Pharmaceuticals, Inc. Presents at Global Online CEO Conference, Jul-16-2014 11:30 AM

Actinium Pharmaceuticals, Inc. Presents at Global Online CEO Conference, Jul-16-2014 11:30 AM.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATNM:US $6.47 USD +0.125

ATNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ATNM.
View Industry Companies
 

Industry Analysis

ATNM

Industry Average

Valuation ATNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 39.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTINIUM PHARMACEUTICALS INC, please visit www.actiniumpharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.